Author Affiliation: Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
The report by Wagner and colleagues1 in
this issue of THE JOURNAL, a pooled analysis of 2 multicenter, double-blind,
randomized placebo-controlled trials evaluating the effect of the selective
serotonin reuptake inhibitor (SSRI) sertraline on children and adolescents
aged 6 to 17 years with major depressive disorder (MDD), constitutes the largest
positive psychopharmacological study of MDD in this age group reported to
date. The primary outcome was change from baseline in the Children's Depression
Rating Scale–Revised (CDRS-R), with a prospectively determined primary
efficacy measure of the CDRS-R Best Description of Child total score; secondary
efficacy measures included the proportion of CDRS-R responders, defined as
patients who had at least a 40% decrease in the adjusted CDRS-R total score.
The results indicate a statistically significant improvement for patients
receiving active drug vs those receiving placebo.
Varley CK. Psychopharmacological Treatment of Major Depressive Disorder in Children and Adolescents. JAMA. 2003;290(8):1091–1093. doi:10.1001/jama.290.8.1091
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: